Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

You are correct.

There are very few companies developing therapies. Many developing vaccines but there are almost none developing treatments for the lung injury. The market is our's for the taking.

We are scaling up drug manufacturing to prepare for our trial. There are very few others ongoing. We are definitely out of the gate in the lead. There is room for multiple treatments in this field. There's not just going to be one winner.